<SEC-DOCUMENT>0001628280-21-003894.txt : 20210304
<SEC-HEADER>0001628280-21-003894.hdr.sgml : 20210304
<ACCEPTANCE-DATETIME>20210304082305
ACCESSION NUMBER:		0001628280-21-003894
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210304
ITEM INFORMATION:		Results of Operations and Financial Condition
FILED AS OF DATE:		20210304
DATE AS OF CHANGE:		20210304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		21712649

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xfor-20210304.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:0c50b242-5944-44ee-806a-ccbed3795822,g:e70a8ec4-4aa9-4be8-ae62-dad3fb8f4e67,d:c427d28fc8dc45b38018c1d538eb045d--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xfor-20210304</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF80L2ZyYWc6NjQyMWIzZWY2NDgxNDlkYjg0ZjU5OWFkODdmNTU1YTMvdGFibGU6ZDQ1MmU0YzQ0YmVhNDA4Njk5ZjQ1YzczMmQ3MDI5MzcvdGFibGVyYW5nZTpkNDUyZTRjNDRiZWE0MDg2OTlmNDVjNzMyZDcwMjkzN18wLTEtMS0xLTA_9c00ff57-4d3a-4848-a19e-4d87d098e59a">0001501697</ix:nonNumeric><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF80L2ZyYWc6NjQyMWIzZWY2NDgxNDlkYjg0ZjU5OWFkODdmNTU1YTMvdGFibGU6ZDQ1MmU0YzQ0YmVhNDA4Njk5ZjQ1YzczMmQ3MDI5MzcvdGFibGVyYW5nZTpkNDUyZTRjNDRiZWE0MDg2OTlmNDVjNzMyZDcwMjkzN18xLTEtMS0xLTA_979ee901-7f66-4b91-9410-9542e6b103dd">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xfor-20210304.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-04</xbrli:startDate><xbrli:endDate>2021-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia893253352f04d268831945dac6d339e_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic427d28fc8dc45b38018c1d538eb045d_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.844%"><tr><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.068%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:22.988%"><tr><td style="width:1.0%"></td><td style="width:57.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">FORM  </span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6NGExNTYxYmE0MDExNGQyYjk1YTc3MzU1MDIxYWU3NDIvdGFibGVyYW5nZTo0YTE1NjFiYTQwMTE0ZDJiOTVhNzczNTUwMjFhZTc0Ml8wLTEtMS0xLTA_8af99a72-72c2-4d96-9144-74b61b2f6abf">8-K</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Data of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8yMjA_61ffab3a-71da-4faf-9d49-a3a375f41ee6">March 4, 2021</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:69.396%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6NGRjMDI0ZWJlNWYyNGE1YTljN2NmNTcwMjYwNjM0MzIvdGFibGVyYW5nZTo0ZGMwMjRlYmU1ZjI0YTVhOWM3Y2Y1NzAyNjA2MzQzMl8xLTAtMS0xLTA_f1c669ee-6e50-4551-899a-fb2e9c2cf584">X4 PHARMACEUTICALS, INC.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.793%"><tr><td style="width:1.0%"></td><td style="width:32.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6NWQ3Mjc3ZWI2ZjY4NGY4ZmJhODMyYWIxMzY0ZWYzNjgvdGFibGVyYW5nZTo1ZDcyNzdlYjZmNjg0ZjhmYmE4MzJhYjEzNjRlZjM2OF8wLTAtMS0xLTA_456aa324-6abb-4cbc-9140-1fc76d7259a2">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6NWQ3Mjc3ZWI2ZjY4NGY4ZmJhODMyYWIxMzY0ZWYzNjgvdGFibGVyYW5nZTo1ZDcyNzdlYjZmNjg0ZjhmYmE4MzJhYjEzNjRlZjM2OF8wLTItMS0xLTA_ae15cbe7-ce5b-4d35-89e0-3744a77cfdc8">001-38295</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6NWQ3Mjc3ZWI2ZjY4NGY4ZmJhODMyYWIxMzY0ZWYzNjgvdGFibGVyYW5nZTo1ZDcyNzdlYjZmNjg0ZjhmYmE4MzJhYjEzNjRlZjM2OF8wLTQtMS0xLTA_1132d640-fab5-410d-abee-9608d519176c">27-3181608</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.373%"><tr><td style="width:1.0%"></td><td style="width:20.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6ZThiNjI0MGI5YzcyNDM1ZmJjZmM3OTQ0ZjZmNDZmOGYvdGFibGVyYW5nZTplOGI2MjQwYjljNzI0MzVmYmNmYzc5NDRmNmY0NmY4Zl8wLTAtMS0xLTA_dd263fca-7d15-4d02-83e5-a241aae6a810">61 North Beacon Street,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6ZThiNjI0MGI5YzcyNDM1ZmJjZmM3OTQ0ZjZmNDZmOGYvdGFibGVyYW5nZTplOGI2MjQwYjljNzI0MzVmYmNmYzc5NDRmNmY0NmY4Zl8wLTEtMS0xLTA_676cb8be-c709-4246-8f2f-b46a44780ca3">4th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6ZThiNjI0MGI5YzcyNDM1ZmJjZmM3OTQ0ZjZmNDZmOGYvdGFibGVyYW5nZTplOGI2MjQwYjljNzI0MzVmYmNmYzc5NDRmNmY0NmY4Zl8xLTAtMS0xLTA_9210c4e3-7cf4-4f81-9d25-d8adb7bec7c1">Boston,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6ZThiNjI0MGI5YzcyNDM1ZmJjZmM3OTQ0ZjZmNDZmOGYvdGFibGVyYW5nZTplOGI2MjQwYjljNzI0MzVmYmNmYzc5NDRmNmY0NmY4Zl8xLTEtMS0xLTA_dd2d9b50-218d-48bd-8265-765051012f00">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6ZThiNjI0MGI5YzcyNDM1ZmJjZmM3OTQ0ZjZmNDZmOGYvdGFibGVyYW5nZTplOGI2MjQwYjljNzI0MzVmYmNmYzc5NDRmNmY0NmY4Zl8xLTMtMS0xLTA_f1ab7df7-2fb8-4a90-beb5-d1bf62c5f2fc">02134</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDcy_51c91e7e-207c-4240-a748-f870e792a20e">857</ix:nonNumeric>) <ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDgw_d7dd6534-17db-4d5f-8cb2-13ef0f3a09fe">529-8300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia893253352f04d268831945dac6d339e_D20210108-20210108" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDY5_608beb5c-b748-4d8f-a28d-9f3b4d471229">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia893253352f04d268831945dac6d339e_D20210108-20210108" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDc1_58f72bf5-25d6-4dff-af53-67da0a97791c">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia893253352f04d268831945dac6d339e_D20210108-20210108" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDc3_59a86650-4cc0-4b99-bc44-fd0a6ce3ad67">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia893253352f04d268831945dac6d339e_D20210108-20210108" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDc4_e014bf1b-4c93-456c-b2fa-46f370191a40">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule  13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.252%"><tr><td style="width:1.0%"></td><td style="width:34.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6YjBjZTM3ODMwZmZiNDlmZGFjYmUyMmNjN2ZhZWU0MDMvdGFibGVyYW5nZTpiMGNlMzc4MzBmZmI0OWZkYWNiZTIyY2M3ZmFlZTQwM18xLTAtMS0xLTA_5e9f30ac-760b-431c-9425-bb9e605c39a0">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6YjBjZTM3ODMwZmZiNDlmZGFjYmUyMmNjN2ZhZWU0MDMvdGFibGVyYW5nZTpiMGNlMzc4MzBmZmI0OWZkYWNiZTIyY2M3ZmFlZTQwM18xLTItMS0xLTA_0574a6ce-413d-42b9-9892-c49b15ceaa08">XFOR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6YjBjZTM3ODMwZmZiNDlmZGFjYmUyMmNjN2ZhZWU0MDMvdGFibGVyYW5nZTpiMGNlMzc4MzBmZmI0OWZkYWNiZTIyY2M3ZmFlZTQwM18xLTQtMS0xLTA_665bbb11-34a5-4ec1-a2d3-2c0079a1a7cf">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter).          Emerging growth company&#160;<ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDc5_624f1300-49d5-41bd-95f6-a81c73df7262">&#9746;</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act&#160;&#160;<ix:nonNumeric contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDcx_6e03bc98-ef84-41b2-96a9-65bff14a3535">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic427d28fc8dc45b38018c1d538eb045d_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2.02</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Results of Operations and Financial Condition</span></div></td></tr></table></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 4, 2021, X4 Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results and other business highlights for the fourth quarter and full year ended December 31, 2020. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in this Item 2.02 in the Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Item 9.01 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">            </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Financial Statements and Exhibits. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">(d) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">         </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Exhibits. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%;text-decoration:underline">Exhibit No.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%;text-decoration:underline">                        </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%;text-decoration:underline">Description</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.993%"><tr><td style="width:1.0%"></td><td style="width:26.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a991pressreleasedatedmarch.htm">Press release of X4 Pharmaceuticals Inc. dated March 4, 2021.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic427d28fc8dc45b38018c1d538eb045d_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="padding-left:252pt"><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  March 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Derek Meisner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derek Meisner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General Counsel</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a991pressreleasedatedmarch.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9aab4829232f45e0bba2d50f034f240f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><img alt="x4logo1a.jpg" src="x4logo1a.jpg" style="height:69px;margin-bottom:5pt;vertical-align:text-bottom;width:95px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:95%">X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update</font></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font><br></font></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">2021 expected to be a year of key value-driving catalysts as company advances multiple  clinical programs with lead candidate mavorixafor </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Company anticipates completing full enrollment in WHIM Phase 3 trial in 2021 and presenting clinical data from the ongoing Phase 1b Waldenstr&#246;m&#8217;s trial throughout the year </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:95%">Conference call today at 8&#58;30 a.m. ET</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">BOSTON, Mass. &#8211; March 4, 2021 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">-- </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">X4 Pharmaceuticals, Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> (Nasdaq&#58; XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today reported financial results for the fourth quarter and full year ended December 31, 2020. The company also provided an update on its lead product candidate, mavorixafor, a novel small molecule currently being evaluated in a Phase 3 clinical trial (</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4WHIM</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">) for patients with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome and in two Phase 1b trials for patients with Waldenstr&#246;m&#8217;s macroglobulinemia (Waldenstr&#246;m&#8217;s) and Severe Congenital Neutropenia (SCN), respectively.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;As many companies did, we encountered a number of unexpected challenges in 2020, most notably the COVID-19 pandemic. However, I could not be prouder of our accomplishments, as we remained steadfast in our commitment to advance our lead candidate, mavorixafor, in a number of rare disease indications,&#8221; said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. &#8220;We believe that we have much to look forward to this year, as we have overcome these obstacles, have made significant progress in advancing our clinical and research programs, and assembled an exceptional team to execute on our 2021 goals and beyond.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;On the clinical front, we continue to expect top-line data from our Phase 3 WHIM trial in 2022 and, as our Phase 1b Waldenstr&#246;m&#8217;s trial is progressing well, we continue to expect initial data from that study in the first half of 2021, with a more fulsome dataset expected towards the end of 2021. We also anticipate initial data from our SCN Phase 1b trial in 2021.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Recent Highlights</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">Received Fast Track and Rare Pediatric Designations (RPD) from the FDA for Mavorixafor for the treatment of WHIM Syndrome</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#58; These FDA designations further recognize WHIM as a serious condition with a clear unmet need in both adult and pediatric populations. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.75pt">Through the Fast Track program, X4 will be eligible for more frequent meetings with the FDA to discuss the drug&#8217;s development plan, protocols and clinical data that would support mavorixafor&#8217;s potential approval for WHIM. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.75pt">Under the RPD program, a sponsor who receives an approval for a drug for a &#8220;rare pediatric disease&#8221; and a Fast Track designation may qualify for a voucher that can be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">redeemed to receive a priority review by the FDA for any subsequent marketing application for a different product. Such a voucher is transferable and may be sold. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.75pt">Mavorixafor was previously granted Breakthrough Therapy Designation by the FDA, as well as Orphan Drug status by the FDA and the European Commission for the treatment of WHIM syndrome.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">Strengthened Leadership Team</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#58; During the Fourth Quarter of 2020&#58; </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.75pt;text-decoration:underline">Diego Cadavid, M.D.</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, joined as Chief Medical Officer, bringing more than 20 years of industry experience and having led multiple programs through all phases of clinical development, including small molecules and biologics for the treatment of rare and immunological diseases.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.75pt;text-decoration:underline">Art Taveras, Ph.D.</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, joined as Chief Scientific Officer with more than 30 years of experience leading small molecule research and development programs focused on cancer, dysregulated immune disorders, neurodegeneration, and metabolic diseases.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#9702;</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.75pt;text-decoration:underline">Alison Lawton</font><font style="color:#222222;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> was appointed to the company&#8217;s Board of Directors, bringing more than 30 years of experience across a full spectrum of drug development and commercial roles and having previously served on X4&#8217;s corporate advisory board and as consulting Chief Operating Officer. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Fourth Quarter 2020 Financial Results </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:13.8pt">Cash, Cash Equivalents &#38; Restricted Cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#58; X4 had $80.7 million </font><font style="background-color:#ffffff;color:#201f1e;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">in cash, cash equivalents and restricted cash as of December 31, 2020. X4 continues to expect that its cash and cash equivalents will fund company operations into 2022. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:14.15pt">Research and Development Expenses </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">were $12.3 million and $41.9 million for the fourth quarter and full year ended December 31, 2020, respectively, as compared to $7.1 million and $30.2 million for the comparable periods in 2019, respectively. R&#38;D expenses include $0.6 million and $2.3 million of certain non-cash expenses for the fourth quarter and fully year ended December 31, 2020, respectively. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">General and Administrative Expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> were $5.4 million and $20.9 million for the fourth quarter and full year ended December 31, 2020, respectively, as compared to $3.9 million and $17.6 million for the comparable periods in 2019, respectively. G&#38;A expenses include $0.8 million and $3.1 million of certain non-cash expenses for the fourth quarter and full year ended December 31, 2020, respectively.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">Net Loss&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">X4 reported net losses of $18.4 million and $62.1 million for the fourth quarter and full year ended December 31, 2020 as compared to net losses of $10.8 million and $52.8 million for the comparable periods in 2019, respectively. Net losses include $1.4 million and $5.4 million of certain non-cash expenses for the fourth quarter and full year ended December 31, 2020, respectively. Net losses in the full year of 2019 included a $3.9 million loss on the sale of non-financial assets.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Conference Call and Webcast </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Company will host a conference call and webcast today at 8&#58;30 a.m. ET to discuss these financial results and business highlights. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009  internationally, followed by the conference ID&#58; 1053189. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals&#8217; website at </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">www.x4pharma.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.  Following the completion of the call, a webcast replay of the conference call will be available on the website.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About X4 Pharmaceuticals</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company&#8217;s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials &#8211; in combination with ibrutinib in patients with Waldenstr&#246;m&#8217;s macroglobulinemia, and as monotherapy in patients with Severe Congenital Neutropenia. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">www.x4pharma.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; or other similar terms or expressions that concern X4's expectations, strategy, plans or intentions. Forward-looking statements include, without limitation, statements regarding the clinical development of mavorixafor and  X4's other product candidates or programs, the potential benefits resulting from Fast Track and Rare Pediatric Disease designations, and the company's cash runway. Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, the risks and uncertainties described in the section entitled &#8220;Risk Factors&#8221; in X4&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 5, 2020, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(Tables Follow)</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9aab4829232f45e0bba2d50f034f240f_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">X4 PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,298&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,065&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,932&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,163&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,357&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,942&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,640&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on transfer of non-financial assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,655&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,875&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,874&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,703&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,655)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,875)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,874)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,703)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(745)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,109)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,104)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,400)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,837)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,983)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,807)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,400)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,837)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,131)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,807)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments related to convertible preferred stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(592)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,400)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,837)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,131)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,399)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders- basic and diluted </font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.91)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.66)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.09)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.63)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding-basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,174&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,466&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,077&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,530&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">X4 PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,131)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52,807)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,376&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,988&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,063)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,236)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58,818)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,055)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities </font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,362)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><font><br></font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,232&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,394&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,661&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash, cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><font><br></font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,384)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,588&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,086&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><font><br></font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,498&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,702&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,086&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">X4 PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:62.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents </font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,708&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,184&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development incentive receivable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">917&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,998&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,682&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,096&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,307&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,278&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,109&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,109&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,960&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,959&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,258&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,949&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,871&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,698&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities&#58; </font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,144&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,088&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,018&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,461&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">898&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,948&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,447&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, including accretion, net of discount</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,178&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,097&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,484&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,918&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,072&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,478&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,799&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,220&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders' equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,871&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,698&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Contacts&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#008080;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Daniel Ferry (Investors)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">      </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                            </font></div><div><font style="color:#008080;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Managing Director </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                      </font><font style="color:#008080;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div><font style="color:#008080;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">LifeSci Advisors</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                            </font></div><div><font style="background-color:#ffffff;color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">daniel&#64;lifesciadvisors.com</font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                       </font></div><div><font style="color:#008080;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(617) 430-7576</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                             </font></div><div><font><br></font></div><div><font style="color:#008080;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">M&#243;nica Rouco Molina (Media)</font></div><div><font style="color:#008080;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Senior Account Executive</font></div><div><font style="color:#008080;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">LifeSci Communications</font></div><div><font style="background-color:#ffffff;color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">mroucomolina&#64;lifescicomms.com</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>xfor-20210304.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0c50b242-5944-44ee-806a-ccbed3795822,g:e70a8ec4-4aa9-4be8-ae62-dad3fb8f4e67-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xfor="http://www.x4pharma.com/20210304" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.x4pharma.com/20210304">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20210304_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20210304_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20210304_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20210304_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.x4pharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>xfor-20210304_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0c50b242-5944-44ee-806a-ccbed3795822,g:e70a8ec4-4aa9-4be8-ae62-dad3fb8f4e67-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/Cover" xlink:type="simple" xlink:href="xfor-20210304.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.x4pharma.com/role/Cover" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>xfor-20210304_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0c50b242-5944-44ee-806a-ccbed3795822,g:e70a8ec4-4aa9-4be8-ae62-dad3fb8f4e67-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.x4pharma.com/role/Cover" xlink:type="simple" xlink:href="xfor-20210304.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.x4pharma.com/role/Cover" xlink:type="extended" id="ibb2ae2d817434a65be0eb4605f4cb121_Cover"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>xfor-20210304_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0c50b242-5944-44ee-806a-ccbed3795822,g:e70a8ec4-4aa9-4be8-ae62-dad3fb8f4e67-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_b8f8c108-27a8-4e7f-9946-972f0e588c29_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b7e9a5d3-df50-47e9-aa04-adfa9f118820_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7dd830e6-d0a9-4d24-be56-785718964ad6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_359e5c44-f71f-4582-9343-4bf286a49d27_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_0ed479b1-f4bc-4f68-9710-3a3fa86b0763_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_10e19c89-6f6a-4989-8acb-3703b0ad28f0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_17c4b0d2-777e-4acb-bbbd-8169507eb2e2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_abf2f8c3-c1f5-402f-a59e-05830ce176fb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cad4d533-a2e4-4076-bc63-28616c6c5875_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_163ca019-50b6-40b7-945b-86174ecb219c_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_097dd0fb-08f2-4323-93bc-d2769e4df17b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_714aa1e8-dc0b-4b33-9a6c-df97a5aeec17_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_17ca3714-36a1-4496-9b3b-a4664fb57be3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_97f2cca0-7c3f-406d-87ca-3a8b0a48f2ab_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_914e01c1-4734-4043-8dba-a4f863aad466_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_01f49987-1f5a-488e-aa40-e22968e2b67f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_526a6f81-1952-4adb-8c0a-e52668475842_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_0e7a3bef-8521-4893-a193-16ac2b7985c0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_68a8d8d2-b813-48a0-b365-eed815731825_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_47e132bc-68f7-4c86-8ede-5f921d872f4e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_345b639b-f33e-4701-97a6-ce927aa22fd2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_81469609-722f-472e-8541-9ba347933831_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7d02061e-16ba-4d49-8fea-efc98862290f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_98567bee-3e40-4f24-b3ea-fdf456b29e1f_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>xfor-20210304_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0c50b242-5944-44ee-806a-ccbed3795822,g:e70a8ec4-4aa9-4be8-ae62-dad3fb8f4e67-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/Cover" xlink:type="simple" xlink:href="xfor-20210304.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e9261bc5-b405-4628-9bb7-923462cb35bd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_DocumentType_e9261bc5-b405-4628-9bb7-923462cb35bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_72f48d9d-55ac-427f-9374-518f9032178c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_DocumentPeriodEndDate_72f48d9d-55ac-427f-9374-518f9032178c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1efae665-4c77-4a75-8166-88a3a5d7ba44" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_EntityRegistrantName_1efae665-4c77-4a75-8166-88a3a5d7ba44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b2be3d02-1160-41d3-8258-b6b7740424ed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b2be3d02-1160-41d3-8258-b6b7740424ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_af43a417-0ec9-4709-a2f2-0f5ec59a9bb0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_EntityFileNumber_af43a417-0ec9-4709-a2f2-0f5ec59a9bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ddd280a0-1e52-4ccc-bd62-a970ec7d19d5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_EntityTaxIdentificationNumber_ddd280a0-1e52-4ccc-bd62-a970ec7d19d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a8442d89-cf0b-4909-8e44-5de64017a64f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_EntityAddressAddressLine1_a8442d89-cf0b-4909-8e44-5de64017a64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_8ccb8ffb-b60c-4cad-b8de-33fec9df3c5e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_EntityAddressAddressLine2_8ccb8ffb-b60c-4cad-b8de-33fec9df3c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9c98fe77-526b-4b3e-8826-840b6e86ce27" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_EntityAddressCityOrTown_9c98fe77-526b-4b3e-8826-840b6e86ce27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7e4fe51a-f525-4094-8e46-5664c939825a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_EntityAddressStateOrProvince_7e4fe51a-f525-4094-8e46-5664c939825a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1cd3c24b-8d6b-4d92-957f-1369966fffe0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_EntityAddressPostalZipCode_1cd3c24b-8d6b-4d92-957f-1369966fffe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f85c00ca-21fa-4c22-abab-94fb11681e7e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_CityAreaCode_f85c00ca-21fa-4c22-abab-94fb11681e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8abbda08-6400-4f17-ac22-c363229e257a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_LocalPhoneNumber_8abbda08-6400-4f17-ac22-c363229e257a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a6c4ff6b-ca13-427f-a6a0-ef0c50b0c3fc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_WrittenCommunications_a6c4ff6b-ca13-427f-a6a0-ef0c50b0c3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_10fa26cf-80b6-4916-91fa-528d504ce9fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_SolicitingMaterial_10fa26cf-80b6-4916-91fa-528d504ce9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_0146ab92-82d2-402e-b8fd-bc2ec9c7bc64" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_PreCommencementTenderOffer_0146ab92-82d2-402e-b8fd-bc2ec9c7bc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_18dadabd-8aae-4c5f-950a-8cc95dca56d9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_18dadabd-8aae-4c5f-950a-8cc95dca56d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_36cc78d6-4116-4054-ba05-dd4cbd3b9735" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_Security12bTitle_36cc78d6-4116-4054-ba05-dd4cbd3b9735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f81e72ec-10d8-4629-8f20-71bf7b40869b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_TradingSymbol_f81e72ec-10d8-4629-8f20-71bf7b40869b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_43530736-0e9c-43d9-957b-21a52cac5a58" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_SecurityExchangeName_43530736-0e9c-43d9-957b-21a52cac5a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3d71135f-0ba1-4cd4-a8aa-422a6f6c732a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_EntityEmergingGrowthCompany_3d71135f-0ba1-4cd4-a8aa-422a6f6c732a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_2bf9a70c-cc8b-4d69-99ea-c5ffa89f047c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_EntityExTransitionPeriod_2bf9a70c-cc8b-4d69-99ea-c5ffa89f047c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c8b74ac9-9b2d-4ce4-b425-374aaed05376" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_EntityCentralIndexKey_c8b74ac9-9b2d-4ce4-b425-374aaed05376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2561ccb9-e577-4242-a92f-42389d5a5d35" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_781791bb-ad77-4676-b597-4ab9bd831e03" xlink:to="loc_dei_AmendmentFlag_2561ccb9-e577-4242-a92f-42389d5a5d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>x4logo1a.jpg
<TEXT>
begin 644 x4logo1a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UI=&-H($)U
M8VML97D   60 P "    %   $*:0!  "    %   $+J2D0 "     S,Q  "2
MD@ "     S,Q  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
M   ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,082
M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3
ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C
MY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:,TGK7$>(O$.N:)J)B
M_<O ^6B?9U&>GU'%7&+F[(SJ5%35V=QFBN!T+QQ<7&I)#J?EB*3Y0R+C:>WX
M5WH(Q1.#@[,5.K&JKQ%S1G-8OB77DT/3_,7#3R'$2'N?6N*3QYK4D@5?(8DX
M&(\Y-.-*4E=&=3$PIRY7N>GY%%4-)-\VGQOJ93[0W)5!@*/3ZU>!J'H="=U<
M7-)D5Q?B;QC+I^H_9-,V,T?^M++G)]!1H6M>(=2U!$GB2&WQN>0Q$9'L:T]E
M+EYCG^L0Y^1':T4@Z"EK(Z0K+UW1HM9TY[=P _6-_P"XW8_T/M6I133:=T3*
M*DK,\0O;273[V2WG5DDC;GVQ7H'A?Q1#-HTBZA(%DM(^2?XT'^<4[QIH"W]D
MU]!A;B $MVWJ/ZCM7FW*Y_7'>N]6K0\SQWS86IIL:.NZM+K6IO<R$A<[8T_N
MC_/6NH\$>'.5U2\7I_J$([_WO\*Q?">@?VO?[YR/LUN07YY;OBO4XT"(%10
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M,XZU4T6&2WT*RAF4K(D"JRGL<5>KCJ3<GJ>E1I1IQT04445F;A1110 4444
2&*,444 )BC:*** %HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>xfor-20210304_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xfor-20210304.xsd" xlink:type="simple"/>
    <context id="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="ia893253352f04d268831945dac6d339e_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF80L2ZyYWc6NjQyMWIzZWY2NDgxNDlkYjg0ZjU5OWFkODdmNTU1YTMvdGFibGU6ZDQ1MmU0YzQ0YmVhNDA4Njk5ZjQ1YzczMmQ3MDI5MzcvdGFibGVyYW5nZTpkNDUyZTRjNDRiZWE0MDg2OTlmNDVjNzMyZDcwMjkzN18wLTEtMS0xLTA_9c00ff57-4d3a-4848-a19e-4d87d098e59a">0001501697</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF80L2ZyYWc6NjQyMWIzZWY2NDgxNDlkYjg0ZjU5OWFkODdmNTU1YTMvdGFibGU6ZDQ1MmU0YzQ0YmVhNDA4Njk5ZjQ1YzczMmQ3MDI5MzcvdGFibGVyYW5nZTpkNDUyZTRjNDRiZWE0MDg2OTlmNDVjNzMyZDcwMjkzN18xLTEtMS0xLTA_979ee901-7f66-4b91-9410-9542e6b103dd">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6NGExNTYxYmE0MDExNGQyYjk1YTc3MzU1MDIxYWU3NDIvdGFibGVyYW5nZTo0YTE1NjFiYTQwMTE0ZDJiOTVhNzczNTUwMjFhZTc0Ml8wLTEtMS0xLTA_8af99a72-72c2-4d96-9144-74b61b2f6abf">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8yMjA_61ffab3a-71da-4faf-9d49-a3a375f41ee6">2021-03-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6NGRjMDI0ZWJlNWYyNGE1YTljN2NmNTcwMjYwNjM0MzIvdGFibGVyYW5nZTo0ZGMwMjRlYmU1ZjI0YTVhOWM3Y2Y1NzAyNjA2MzQzMl8xLTAtMS0xLTA_f1c669ee-6e50-4551-899a-fb2e9c2cf584">X4 PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6NWQ3Mjc3ZWI2ZjY4NGY4ZmJhODMyYWIxMzY0ZWYzNjgvdGFibGVyYW5nZTo1ZDcyNzdlYjZmNjg0ZjhmYmE4MzJhYjEzNjRlZjM2OF8wLTAtMS0xLTA_456aa324-6abb-4cbc-9140-1fc76d7259a2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6NWQ3Mjc3ZWI2ZjY4NGY4ZmJhODMyYWIxMzY0ZWYzNjgvdGFibGVyYW5nZTo1ZDcyNzdlYjZmNjg0ZjhmYmE4MzJhYjEzNjRlZjM2OF8wLTItMS0xLTA_ae15cbe7-ce5b-4d35-89e0-3744a77cfdc8">001-38295</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6NWQ3Mjc3ZWI2ZjY4NGY4ZmJhODMyYWIxMzY0ZWYzNjgvdGFibGVyYW5nZTo1ZDcyNzdlYjZmNjg0ZjhmYmE4MzJhYjEzNjRlZjM2OF8wLTQtMS0xLTA_1132d640-fab5-410d-abee-9608d519176c">27-3181608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6ZThiNjI0MGI5YzcyNDM1ZmJjZmM3OTQ0ZjZmNDZmOGYvdGFibGVyYW5nZTplOGI2MjQwYjljNzI0MzVmYmNmYzc5NDRmNmY0NmY4Zl8wLTAtMS0xLTA_dd263fca-7d15-4d02-83e5-a241aae6a810">61 North Beacon Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6ZThiNjI0MGI5YzcyNDM1ZmJjZmM3OTQ0ZjZmNDZmOGYvdGFibGVyYW5nZTplOGI2MjQwYjljNzI0MzVmYmNmYzc5NDRmNmY0NmY4Zl8wLTEtMS0xLTA_676cb8be-c709-4246-8f2f-b46a44780ca3">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6ZThiNjI0MGI5YzcyNDM1ZmJjZmM3OTQ0ZjZmNDZmOGYvdGFibGVyYW5nZTplOGI2MjQwYjljNzI0MzVmYmNmYzc5NDRmNmY0NmY4Zl8xLTAtMS0xLTA_9210c4e3-7cf4-4f81-9d25-d8adb7bec7c1">Boston,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6ZThiNjI0MGI5YzcyNDM1ZmJjZmM3OTQ0ZjZmNDZmOGYvdGFibGVyYW5nZTplOGI2MjQwYjljNzI0MzVmYmNmYzc5NDRmNmY0NmY4Zl8xLTEtMS0xLTA_dd2d9b50-218d-48bd-8265-765051012f00">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6ZThiNjI0MGI5YzcyNDM1ZmJjZmM3OTQ0ZjZmNDZmOGYvdGFibGVyYW5nZTplOGI2MjQwYjljNzI0MzVmYmNmYzc5NDRmNmY0NmY4Zl8xLTMtMS0xLTA_f1ab7df7-2fb8-4a90-beb5-d1bf62c5f2fc">02134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDcy_51c91e7e-207c-4240-a748-f870e792a20e">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDgw_d7dd6534-17db-4d5f-8cb2-13ef0f3a09fe">529-8300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ia893253352f04d268831945dac6d339e_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDY5_608beb5c-b748-4d8f-a28d-9f3b4d471229">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ia893253352f04d268831945dac6d339e_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDc1_58f72bf5-25d6-4dff-af53-67da0a97791c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ia893253352f04d268831945dac6d339e_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDc3_59a86650-4cc0-4b99-bc44-fd0a6ce3ad67">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ia893253352f04d268831945dac6d339e_D20210108-20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDc4_e014bf1b-4c93-456c-b2fa-46f370191a40">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6YjBjZTM3ODMwZmZiNDlmZGFjYmUyMmNjN2ZhZWU0MDMvdGFibGVyYW5nZTpiMGNlMzc4MzBmZmI0OWZkYWNiZTIyY2M3ZmFlZTQwM18xLTAtMS0xLTA_5e9f30ac-760b-431c-9425-bb9e605c39a0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6YjBjZTM3ODMwZmZiNDlmZGFjYmUyMmNjN2ZhZWU0MDMvdGFibGVyYW5nZTpiMGNlMzc4MzBmZmI0OWZkYWNiZTIyY2M3ZmFlZTQwM18xLTItMS0xLTA_0574a6ce-413d-42b9-9892-c49b15ceaa08">XFOR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGFibGU6YjBjZTM3ODMwZmZiNDlmZGFjYmUyMmNjN2ZhZWU0MDMvdGFibGVyYW5nZTpiMGNlMzc4MzBmZmI0OWZkYWNiZTIyY2M3ZmFlZTQwM18xLTQtMS0xLTA_665bbb11-34a5-4ec1-a2d3-2c0079a1a7cf">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDc5_624f1300-49d5-41bd-95f6-a81c73df7262">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOmM0MjdkMjhmYzhkYzQ1YjM4MDE4YzFkNTM4ZWIwNDVkL3NlYzpjNDI3ZDI4ZmM4ZGM0NWIzODAxOGMxZDUzOGViMDQ1ZF8xL2ZyYWc6NDQ1NjgwM2U1NjUwNDNmYWI4YWU1NGUzY2IwY2NkNTYvdGV4dHJlZ2lvbjo0NDU2ODAzZTU2NTA0M2ZhYjhhZTU0ZTNjYjBjY2Q1Nl8xNDcx_6e03bc98-ef84-41b2-96a9-65bff14a3535">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140132805296664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th"><div>Jan. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  04,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">X4 PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3181608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61 North Beacon Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-8300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XFOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MG9A=<]HX%(:ON[]"P^S%[@P)MO@(Z1!F'(=LV>:#!KKM[,Y>"%N )K;DE>4
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ML+G/3U><@8W9%^#Y0BESN+ [_.*+SO!_4$L#!!0    ( .)"9%*#J:4#U $
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #B0F12!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .)"
M9%*S!Z;8[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( .)"9%*97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ XD)D4JT3[9M]
M!   W1$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( .)"9%*#J:4#U $  #(&   -              "
M < ,  !X;"]S='EL97,N>&UL4$L! A0#%     @ XD)D4I>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  #<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="xfor-20210304.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="xfor-20210304.htm">xfor-20210304.htm</File>
    <File>a991pressreleasedatedmarch.htm</File>
    <File>xfor-20210304.xsd</File>
    <File>xfor-20210304_cal.xml</File>
    <File>xfor-20210304_def.xml</File>
    <File>xfor-20210304_lab.xml</File>
    <File>xfor-20210304_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xfor-20210304.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 2,
   "dts": {
    "calculationLink": {
     "local": [
      "xfor-20210304_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "xfor-20210304_def.xml"
     ]
    },
    "inline": {
     "local": [
      "xfor-20210304.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xfor-20210304_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xfor-20210304_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "xfor-20210304.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "xfor",
   "nsuri": "http://www.x4pharma.com/20210304",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20210304.htm",
      "contextRef": "i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.x4pharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20210304.htm",
      "contextRef": "i9a063d6b7f74414bac6b6315ada88c45_D20210304-20210304",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-21-003894-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-003894-xbrl.zip
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MJ3FHZJ ,"ADP4#3##=%9H@81)Q3J!IH=.B-89W1!-1A0PX^0A0HZY/H!:$Y
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M=4X-]*..[WT"^N-C'.).&]%%L$J,^-KR5PD1\S%V/,:&@EEI7AL9%_;'1:<
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MV_M"=RDC GB=B]PD_#1Y_\MG\8]<2 LO1FO:YK684HFYR[?3;YVI,R^BURK
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MP[67437]C-Y$U1W+VVE5JYV1<DDMU"JU:M:E;1&U5L$.VW:%=Q\_Z.72)P>
M$8# T'#)'6 KAY+3.V9R.OM.HO=E]!-S.%C[J)6.7+\P(\1#QS-B[YJN;8=(
M.RS$\K-J56P/&6L+OB9M"WQF3QB6E>0S7DXV7H-WWG+-(?SH!K;UY?\!4$L#
M!!0    ( .)"9%)QVOW![14  -J7   1    >&9O<BTR,#(Q,#,P-"YH=&WM
M/6M7V[BVW\^OT,VY]QRZ%DHD^9VVG,408#)3)RV$,LF7+MF2B8,39VP'DOSZ
MNV4G/ ,$2B"<TC738O3:VMIO;4F?_C/N1^A,)FD8#SZ7:)F4T'^V/OT/QG_]
M=O %U6)_U)>##.TDDF=2H/,PZZ)C(=-3%"1Q'QW'R6EXQC'.V^S$PTD2GG0S
MQ BC-PJ3*O$-XC&=8</1=:SK4F*;F!S[OB>%9CF&S=CF255:A-O2AQJ<.UCW
MI(VY-!D67&B!9P>Z-*U-4?5U9@EF![XM?-WP-)M0VZ?"T&SI$=T0:MAN!K.#
M&0[2:CC.<"K]SZ5NE@VKE<KY^7D9OLLG\5DE'$3A0*H95[*$#](@3OH\ XQ4
M&*$&)C;6:&G6SS@-K_5QKI7CY 0J$EKYR_URZ'=EG^-PD&9\X,MY*^C_]%JS
ML9=$\X9:115[/+VH/KY5?S8,=1RGDI>6+N>UN..')L4P,^>="'DYJ;R#.6:@
M *HS@@F]B@.H$MXSG9NS#\=W5:;:%3AGU>^>MUK.O%(UXH.3SR4YP$>')5AF
MR<76I[[,.%)-L?Q[%)Y]+NW$@PR(%[<F0P#%+[X^ES(YSBIY5Y6M?_SC'Y^R
M,(ODUACP@Q79$HWHGRK%+S]5BJZ]6$RV/HGP#*79))*?2R),AQ&?5 ?Q0 (
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M1RF3(J#!KPO+E#Q[BN>#WU!+ P04    " #B0F12)Z?I.N$*  ".90  %0
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MT>UJ52N8]SO1 ^T=P0<#?7^"Z]@W:-V^".1KI-GGZR0V'^]NI$FG5&L6^(8
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MIJYTP+LZ]=Y<;X0=&.CJI+9)KFG7%>'WT6SUY38!#B4)N 0V" S U'G$J2!
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M]^'</3I]L7HF6OP''J<O_@]02P,$%     @ XD)D4H*&,+D,!P  HS4  !4
M  !X9F]R+3(P,C$P,S T7W!R92YX;6S5FUMOV[@2Q]_S*7R\KX<QKQ(9-%GD
M9-N#8+/;H,VBBWTQ>!G:0FW)H)3&^?9GI"1M;L71QEI$??%%IC3#/W\9SHR4
M-S]OUZO)%TAU496'4[9/IQ,H?16*<G$X_>/B'='3GX_V]M[\BY ___/A;/)+
MY2_74#:3DP2V@3"Y*IKEY%. ^O,DIFH]^52ES\472\A1=]))M;E.Q6+93#CE
M[/&OZ8!Z11V7G"@C)9$2@&B:6>*]@R!RHS3G_UX<0$ZM!H\CK#5$.M#$0L9)
ML$%$IZ.$+.\NNBK*SP?MB[,U3'!R9=U]/9PNFV9S,)M=75WM;UU:[5=I,>.4
MBMG=Z.GM\.V3\5>B&\V,,;/NUZ]#Z^*Y@7A9-OOSM[./?@EK2XJR;FSI6P-U
M<5!W!\\J;YM.\__KU^2[(]IOY&X8:0\1QHE@^]LZ3(_V)I,;.5*U@@\0)^W[
M'Q].'YJ4FZ5-:[OOJ_6L'3 [J1 '=+4[M;G>P.&T+M:;%=P=6R:(A]-MK!)I
MUY0**EN#/]V<./MF=Y.@1E2Z>9[A@=OS6RM_WP?8-E &N)G7G855Y1\,6K6J
M5E_/7%D'J^[H/$ Q[ZYZ[.HF6=_,<\URPYPC-N0YD5F>$:<,?K+.N* % RH>
M3KEUN4:?NT6HP>\OJB\SO# N!J?MAU8/2BB[78*?GAB]4>=EWM_]Y5W@V#D8
MGC'G%7&2*G2>:V*<RXGA K]X)Y0+ SA_W^9#W^^O[7'RDRH%2!A [HS:Y)^N
M\P-X;T?,-C;AA8A?%JNO+K>19(AU:ZH!]+M9''1W.L%91T@)PMG-VGQW<MW,
M&@RKT(T<8MW/(155>%N&7S#NSG,>I0XF$*6L)Y+GD1B12Z*8CH8*SG+M!P3@
M@?%>)/#QD_!R15\9B;=E4S37'V!1M$J4S>]V#7,&$;?$#&GVK1HV5T2S+"-:
M6V%5R)V5<@ BGK/="P@Q7B!VUG,4/)QBWI8V5>J$_XCZPTEU63;I^J0*,'?<
M@0B4$\8R2B0+@FBN-'&9RW-))9<PQ([1PY5>M,BQTS*<VJ. YUVQ@M\OUP[2
MW$8IK&0YH> QU\ZI(99'3FA4X)6QN%'2P4CY9K<7%FKL6+Q0QU$P<&&WIP&U
M*F)Q4YS<3B2$P#6UE#!0',.A]\0%++ZLR7%J>6 FJ,& ^(X3O>C(QD['$ J/
M I7C$' )ZMLW+.Z S:V6D@=MB(_4$6F0=PU8U*L F:0LMYF,@V'RC .]$,G'
MCLBNRHX4#S[7WCL=H\,]D&)^[6T@3@<@0D2,CR$*K^ ?Q(/WPD/_>'C\/67'
MA,<)?GR?+JJK<FZ\T1%0#\4S)-P)P#R;8[(MJ<M 9QYX/C0<W\SW0L/\(&B\
M4-4Q@=&ET^_3>:J^%*7'TAQD!,4LB8IC/4:-;.-?1E2626^$P=3:#DW'(Q_Z
M=;_H#\+(+@*/"93SJF[LZJ]BTQ5=S ?AN71$AQ;W8#@Q*H^$B<R8+(LQPG"%
MRW,>](-DQ#W2@<1]943:"'B<P'9^1ZT\I=X2SJ+%S9%C5NVL(T9&A\6Y9I /
MD7;<M]D/@Q$W2%\LX"LO?'M3;76^K,J[$EQ;YX*EFF":3(F,6(S;=@)>9()S
M USE0VP<C^WV V#$#=&=A'QE"#ZEHFF@/*G6Z\ORMLRNYS;S,D:,7-XR<=/=
MMQD6W!"[.]#4BSC$_9)GC??#8<0=S]TE?64F/E:KPA=-42Y^P\0G%78U9S1:
MGOE(-.;"6%.SC)@VP"FN@Z+2@XE#A(:GEOO1,.)&YXYBOC(*YPE:C@'3WNYN
M</M007J/V4N:4R8SG#LGF@>.63 'K*,C%M.>8QWM<^>S(>Z@?=^#?FB,N,LY
MD+CC0N2TKB\AW9\+T\$&ZP+1U@*F1"IB+DPMT=X;%;Q563##@_+$CWZXC+CC
M.:C0K[W%@+_$;?*:<7=1-"N8B\S['(LE(C%+1N"5),Y214*0W@7A3"Z&N&OR
MV&X_*$;<Y]Q)R%>&X"+9]LG)C]=K5ZVP<L+:"*,;833H]B$C0W3$!<R9B[F3
M5&?&#4#  Z/]EG_$O<R72SB2 /!VZY>V7$#W$(D42M!<9(2"\42*8-JNB<-:
MVBKNK5=6Z0&#P'W;_9[2&G''<F=!1]&I?+N&M$"@_YNJJV:)V]W&EM=S$7+&
M!&YGU%F&&UN0Q.(>AU44MUG,?"[X<!WM9UWHA\?H>Y6[RSL.2K88]\JZ:/6_
M>2QQSETT-J>>>*_;AFN&I!NP!).@:+6)5.9#="R^9[\?'R-N8@XB["C@.$&]
MDEV=8EZ\_16NY^AV+JU'MQT/2#=@0B2Y(@*/6@A4B3P;C(Q'QOMA,>+6YNZ2
MOC(3QU@JA;9<>K>RBSE7&?/>&0*JE:']3QIK>,1/0IN NV$8I,IX8+0? R/N
M9[Y<PL'6_LWLB7AG>.!H[_:']J7]KYZCO?\!4$L! A0#%     @ XD)D4L7;
MV&[L'P   X@! !X              ( !     &$Y.3%P<F5S<W)E;&5A<V5D
M871E9&UA<F-H+FAT;5!+ 0(4 Q0    ( .)"9%)QVOW![14  -J7   1
M          "  2@@  !X9F]R+3(P,C$P,S T+FAT;5!+ 0(4 Q0    ( .)"
M9%*=>=F6A0(  '<)   1              "  40V  !X9F]R+3(P,C$P,S T
M+GAS9%!+ 0(4 Q0    ( .)"9%+B^#:T@ $  ,8"   5              "
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8;6Q02P4&      < !P#6 0  -4\

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
